Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 51ºÚÁϳԹÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The role if follistatin in HIV-associated pre-eclampsia
14th World Congress on Infection Prevention and Control
Siphesihle Mdlalose, Jagedisa Moodley and Thajasvarie Naicker
Department of Optics and Imaging, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.Womens Health and HIV Studies, Department of Obstetrics and Gynaecology, Nelson Mandela School of Medicine, College of Health Sciences, Universityof KwaZulu-Natal, Durban, South
KwaZulu-Natal has a high burden of HIV infection and high blood pressure, specifically pre-eclampsia (PE) in pregnancy.
Follistatin (FS) is an extracellular glycoprotein antagonist of the ligand receptor, Activin-A, involved in PE pathogenesis.
In light of the high maternal mortality and morbidity in SA, we investigated the expression of FS in the duality of HIVassociated
PE. Therefore, the aim of this study was to investigate the role of FS in HIV-associated PE using the Bioplex Multiplex
Immunoassay. The methodology used -serum samples of normotensive and pre-eclamptic women stratified by HIV status
were collected from a large regional hospital in Durban, and their FS expression was analysed using the Bio-Plex® Pro™ Human
Cancer Biomarker Panel 1. Our results revealed that irrespective of HIV status, FS expression was significantly reduced in
pre-eclamptic compared to normotensive pregnancies (2354±353.6 vs 649.5±116.8; p<0.001). However, FS expression did not
differ between HIV +ve vs HIV –ve groups (1727±291.2 vs 1305±306.7; p=0.13)- regardless of pregnancy type. Furthermore,
we detected significant FS expression across all study groups (p<0.05). In conclusion, this study demonstrates a downregulation
of FS expression in PE, possibly due to oxidative stress and its immunoregulatory role in the hyperinflammatory milieu of PE.
Moreover, the fact that FS did not vary by HIV status may be attributed to the effects of HAART regimen adopted in SA. It is
also plausible to assume that the upregulation of FS expression (albeit non-significant) in HIV +ve patients, arises as a result
of the immune response in controlling viral infection. Our novel findings suggest that FS may have a potential predicator test
value early in pregnancy, hence work on this is ongoing.